These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Molecular targets for design of novel inhibitors to circumvent aminoglycoside resistance. Jana S; Deb JK Curr Drug Targets; 2005 May; 6(3):353-61. PubMed ID: 15857293 [TBL] [Abstract][Full Text] [Related]
5. Aminoglycoside Revival: Review of a Historically Important Class of Antimicrobials Undergoing Rejuvenation. Serio AW; Keepers T; Andrews L; Krause KM EcoSal Plus; 2018 Nov; 8(1):. PubMed ID: 30447062 [TBL] [Abstract][Full Text] [Related]
6. Semisynthetic aminoglycoside antibiotics: Development and enzymatic modifications. Kondo S; Hotta K J Infect Chemother; 1999 Mar; 5(1):1-9. PubMed ID: 11810483 [TBL] [Abstract][Full Text] [Related]
7. A novel ruthenium-silver based antimicrobial potentiates aminoglycoside activity against Donkor GY; Anderson GM; Stadler M; Tawiah PO; Orellano CD; Edwards KA; Dahl J-U mSphere; 2023 Oct; 8(5):e0019023. PubMed ID: 37646510 [TBL] [Abstract][Full Text] [Related]
8. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas. Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557 [TBL] [Abstract][Full Text] [Related]
9. Aminoglycosides against carbapenem-resistant Enterobacteriaceae in the critically ill: the pitfalls of aminoglycoside susceptibility. Zavascki AP; Klee BO; Bulitta JB Expert Rev Anti Infect Ther; 2017 Jun; 15(6):519-526. PubMed ID: 28375030 [TBL] [Abstract][Full Text] [Related]
10. [Development of antituberculous drugs: current status and future prospects]. Tomioka H; Namba K Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921 [TBL] [Abstract][Full Text] [Related]
16. Aminoglycoside resistance: a worldwide perspective. Young LS; Hindler J Am J Med; 1986 Jun; 80(6B):15-21. PubMed ID: 3089000 [TBL] [Abstract][Full Text] [Related]
17. Protein kinase inhibitors and antibiotic resistance. Burk DL; Berghuis AM Pharmacol Ther; 2002; 93(2-3):283-92. PubMed ID: 12191620 [TBL] [Abstract][Full Text] [Related]
18. Overcoming Aminoglycoside Enzymatic Resistance: Design of Novel Antibiotics and Inhibitors. Zárate SG; De la Cruz Claure ML; Benito-Arenas R; Revuelta J; Santana AG; Bastida A Molecules; 2018 Jan; 23(2):. PubMed ID: 29385736 [TBL] [Abstract][Full Text] [Related]
19. The aminoglycosides. Edson RS; Terrell CL Mayo Clin Proc; 1991 Nov; 66(11):1158-64. PubMed ID: 1943249 [TBL] [Abstract][Full Text] [Related]
20. Design, Multigram Synthesis, and in Vitro and in Vivo Evaluation of Propylamycin: A Semisynthetic 4,5-Deoxystreptamine Class Aminoglycoside for the Treatment of Drug-Resistant Enterobacteriaceae and Other Gram-Negative Pathogens. Matsushita T; Sati GC; Kondasinghe N; Pirrone MG; Kato T; Waduge P; Kumar HS; Sanchon AC; Dobosz-Bartoszek M; Shcherbakov D; Juhas M; Hobbie SN; Schrepfer T; Chow CS; Polikanov YS; Schacht J; Vasella A; Böttger EC; Crich D J Am Chem Soc; 2019 Mar; 141(12):5051-5061. PubMed ID: 30793894 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]